Last reviewed · How we verify
Tamsulosin Hydrochloride Sustained-Release Capsules
At a glance
| Generic name | Tamsulosin Hydrochloride Sustained-Release Capsules |
|---|---|
| Also known as | Tamsulosin, α1-adrenergic receptor antagonist |
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate (PHASE4)
- Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy (PHASE4)
- The Safety and Effectiveness of Steep Pulse Therapy System for the Ablation of Benign Prostatic Hyperplasia (NA)
- Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome (PHASE4)
- Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: